News

News and Press Releases
Patient Assistance Resources for Those Impacted by Hurricane Florence

In the wake of Hurricane Florence, the Cystic Fibrosis Foundation is offering two vital resources to support CF families affected by this hurricane and its surge.

| 2 min read
Research FDA Approves Kalydeco® for Children With CF Ages 1 to 2

Today, the U.S. Food and Drug Administration approved the use of ivacaftor (Kalydeco®) for children with cystic fibrosis ages 1 to 2 who have at least one mutation that is responsive to ivacaftor.

| 3 min read
Research | CFTR Modulators | Drug Pipeline FDA Expands Use of Orkambi® to Children With CF Ages 2 to 5

The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.

| 3 min read
Health Care Reform | Advocacy | Insurance 27 Patient Groups Express Disappointment in Final Rule on Short-Term, Limited-Duration Insurance Plans

Responding to the U.S. Department of Health and Human Services final rule on short-term, limited-duration insurance plans, the Cystic Fibrosis Foundation joined 26 other nonpartisan patient and consumer groups to voice concern that these plans will split the market and jeopardize access to affordable, adequate health care for people living with pre-existing conditions.

| 3 min read
Research | Drug Pipeline Drug Shows Promise in Reducing Inflammation in People With Cystic Fibrosis

Celtaxsys Inc. reported promising results today from an early stage clinical trial of a potential anti-inflammatory drug for people with cystic fibrosis.

| 2 min read
Health Care Reform | Our Advocacy Work | Insurance CF Foundation Responds to Final Short-Term, Limited-Duration Health Insurance Rule

Yesterday, the U.S. Department of Health and Human Services finalized a rule expanding short-term, limited-duration insurance plans -- threatening access to adequate, affordable coverage for people with cystic fibrosis who rely on the individual marketplace.

| 2 min read
Our Advocacy Work Patient Groups Decry Administration’s Latest Effort to Undermine Quality and Affordable Health Care

Responding to the Trump administration's recent decision to freeze risk adjustment payments, the Cystic Fibrosis Foundation joined 13 other nonpartisan patient groups to voice disappointment in the latest administrative efforts to undermine adequate and affordable health care for people with pre-existing conditions. 

| 3 min read
Advocacy CF Teen Advocates Visit Capitol Hill for 10th Annual Teen Advocacy Day

More than 200 advocates from 32 states traveled to Washington, D.C., on June 28 for the Cystic Fibrosis Foundation's 10th annual Teen Advocacy Day, which enabled teens to meet with their elected officials on Capitol Hill to fight for access to high-quality, specialized care for their friends and loved ones living with CF.

| 3 min read
Advocacy CF Foundation Responds to Justice Department Decision

The Department of Justice's decision to no longer defend critical provisions of the Affordable Care Act (ACA) risks health insurance coverage for people with cystic fibrosis and other pre-existing conditions.

| 2 min read
Our Advocacy Work Cystic Fibrosis Foundation Responds to ICER Review of CFTR Modulators

The Cystic Fibrosis Foundation responds to the Institute for Clinical and Economic Review's assessment of the comparative clinical effectiveness and value of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.

| 4 min read